ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025
Heavy-Atom Free Bodipy-Borafluorene Photosensitizer Decorated with Coumarin Antenna Selectively Staining Endoplasmic Reticulum for Application in PDT.
Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Natural Product-Based Upconversion-Downshifting Photosensitizers in Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- C-BODIPY Dyads Based on Fused-Ring Organoboron Scaffolds for Efficient Photodynamic Therapy TargetingJournal of medicinal chemistry · 2026Article
- Decontamination from water pollutants and pathogens by electrospun nanofibers doped with heavy-atom-free borafluorene-BODIPY photosensitizers.Beilstein journal of nanotechnology · 2026Article
- The Current State of Research in the Field of Photosensitizers and Photoactivators for Photodynamic/Photothermal Cancer Therapy: A Review.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The organelle-localized photodynamic therapy (PDT) has become a promising strategy for efficient cancer treatment. The photogeneration of reactive oxygen species in the endoplasmic reticulum (ER) leads to lipid oxidation and causes cell apoptosis or necrosis. However, most of the commercially available ER-localized phototherapeutic agents exhibit dark cytotoxicity related to the presence of heavy atoms. In this contribution, we developed a novel heavy-atom free BODIPY photosensitizer that localizes selectively in the ER with good biocompatibility, small dark cytotoxicity and efficient singlet oxygen generation, causing cellular death in a PDT experiment. The molecular design of the BODIPY PS involves two key elements: (i) replacing of the common BF2 group with the 9-borafluorene which strongly enhances intersystem crossing to the triplet state responsible for photogeneration of singlet oxygen, and (ii) introduction of the pendant coumarin group ensuring ER-localization and serving as light-harvesting antenna for energy transfer to BODIPY core structure. The localization of BODIPY-based PS was confirmed by laser scanning confocal microscopy (LSCM) imaging, and co-staining revealed strong localization within the ER.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.